Arthneeti
AB

Avience Biomedicals Ltd

Q2 FY27Healthcare Equipment & Supplies

Avience Biomedicals Q2 Results 2026 (FY27) statement: Revenue & Margins

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Based on Avience Biomedicals Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

Price₹250
Market cap₹137 Cr
P/E15.7

The short version

Revenue from operations (consolidated) for the half year ended September 30, 2026, is Rs. 3,112.86 Lakhs compared to Rs. 2,681.93 Lakhs for the same period in 2025, reflecting a year-on-year increase. EBITDA for the quarter (year ended September 30, 2026): Rs. 846.52 Lakhs, up 31% YoY (from Rs. 645.31 Lakhs in Sep 2025).

From Avience Biomedicals Ltd's Q2 FY27 earnings-call transcript · updated 11 Nov 2026.

How did Avience Biomedicals' revenue grow in the September 2026 quarter?

  • Revenue from operations (consolidated) for the half year ended September 30, 2026, is Rs. 3,112.86 Lakhs compared to Rs. 2,681.93 Lakhs for the same period in 2025, reflecting a year-on-year increase of Rs. 430.93 Lakhs or approximately 16.07%.
  • Standalone revenue from operations for the half year ended September 30, 2026, is Rs. 2,368.69 Lakhs versus Rs. 1,924.96 Lakhs for the same period in 2025, an increase of Rs. 443.73 Lakhs or roughly 23.06%.

What happened to Avience Biomedicals' margins in Q2 FY27?

See what Avience Biomedicals Ltd said on profitability & margins — free account, 30 seconds.

What capex is Avience Biomedicals planning?

  • Building Construction and Civil Work: ₹1,147.68 Lakhs budgeted; ₹861.60 Lakhs spent; ₹286.08 Lakhs remaining.
  • Purchase of Plant and Machinery: ₹1,147.68 Lakhs budgeted; ₹861.60 Lakhs utilized; ₹286.08 Lakhs pending.
  • Funding of Working Capital Requirements: ₹825.00 Lakhs planned; ₹137.89 Lakhs utilized.
  • General Corporate Purposes: ₹397.16 Lakhs planned; ₹302.30 Lakhs utilized; ₹50.00 Lakhs remaining.
  • The certificate indicates these utilizations are related to proceeds from the Initial Public Offer (IPO).

2 more points from Avience Biomedicals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Equipment & Supplies

Ranked on what management guided this quarter

Guidance-ranked
1OSEL Devices
Rev 1Mar 3
2Molbio Diagnosti
Rev 2Mar 3
3
Rev 2Mar 3
4
Rev 3Mar 1
5
Rev 3Mar 2
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Avience Biomedicals raising money or cutting debt?

See what Avience Biomedicals Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Avience Biomedicals' order book?

See what Avience Biomedicals Ltd said on order book & pipeline — free account, 30 seconds.

Continue your research

What Avience Biomedicals's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

  • Vasa Denticity (Q2 FY27)

    Q2 FY27 revenue from operations: ₹87.10 Cr, up 19.4% YoY (Page 7, 3) . Key investor presentation takeaways from Vasa Denticity Ltd's Q2 FY27 investor presentati

  • Vaidya Sane (Q2 FY27)

    Year-on-year (YoY) change: +23% (from INR 687 Lakhs in Sep 2025) . Key results statement takeaways from Vaidya Sane Ayurved Laboratories Ltd's Q2 FY27 results s

  • Sahajanand Medi (Q2 FY27)

    Slight seasonality in revenue with H2 being marginally higher (~52%) than H1 (~48%). Key concall takeaways from Sahajanand Medical Technologies Ltd's Q2 FY27…

  • Molbio Diagnosti (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹259.0 Cr vs ₹580.3 Cr in Q2 FY26 (significant decrease due to rate contract negotiations). Key investor presentation takeaways

Compare:vs Poly Medicurevs Molbio Diagnostivs Sahajanand Medi

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Avience Biomedicals Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Avience Biomedicals Ltd Q2 FY27 results?

Revenue from operations (consolidated) for the half year ended September 30, 2026, is Rs. 3,112.86 Lakhs compared to Rs. 2,681.93 Lakhs for the same period in 2025, reflecting a year-on-year increase. EBITDA for the quarter (year ended September 30, 2026): Rs. 846.52 Lakhs, up 31% YoY (from Rs. 645.31 Lakhs in Sep 2025).

What is Avience Biomedicals Ltd share price analysis?

Avience Biomedicals Ltd currently shows a neutral. The stock trades at a P/E of 15.7 with a market cap of ₹137 Cr. Investors should review the full earnings analysis for detailed insights.

Is Avience Biomedicals Ltd planning capital expenditure?

Building Construction and Civil Work: ₹1,147.68 Lakhs budgeted; ₹861.60 Lakhs spent; ₹286.08 Lakhs remaining.

Keep Avience Biomedicals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.